Halozyme Therapeutics Archives

Press ESC key to close search

Pharmakon, Athyrium Capital Provide $150MM Debt Financing to Halozyme

Halozyme Therapeutics closed a $150 million royalty-backed debt transacton with investment funds managed by Pharmakon Advisors and Athyrium Capital Management.

BioPharma Provides $150MM Royalty-Backed Debt Financing to Halozyme

Halozyme Therapeutics entered into a $150 million royalty-back debt financing with BioPharma Credit Investments as collateral agent and lender and Athryrium Capital Management as lender.

January 6, 2016 Athyrium Capital Managment | Halozyme Therapeutics | Pharmakon Advisors ABF Journal

<img width="200" src="https://www.abfjournal.com/wp-content/uploads/2020/02/abfj-logo-web-header1-blue.png" alt="ABFJournal" />

Tag Archives: Halozyme Therapeutics

Pharmakon, Athyrium Capital Provide $150MM Debt Financing to Halozyme

BioPharma Provides $150MM Royalty-Backed Debt Financing to Halozyme